Correction: Pre-Clinical Evaluation of a 213Bi-Labeled 2556 Antibody to HIV-1 gp41 Glycoprotein in HIV-1 Mouse Models as a Reagent for HIV Eradication

Correction: Pre-Clinical Evaluation of a 213Bi-Labeled 2556 Antibody to HIV-1 gp41 Glycoprotein in HIV-1 Mouse Models as a Reagent for HIV Eradication

Bibliographic Details
Main Authors:	Ekaterina Dadachova, Scott G. Kitchen, Gregory Bristol, Gayle Cocita Baldwin, Ekaterina Revskaya, Cyril Empig, George B. Thornton, Miroslaw K. Gorny, Susan Zolla-Pazner, Arturo Casadevall
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2012-01-01
Series:	PLoS ONE
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3414582/?tool=EBI

Similar Items

Pre-clinical evaluation of a 213Bi-labeled 2556 antibody to HIV-1 gp41 glycoprotein in HIV-1 mouse models as a reagent for HIV eradication.
by: Ekaterina Dadachova, et al.
Published: (2012-01-01)

Correction: Pre-Clinical Evaluation of a Bi-Labeled 2556 Antibody to HIV-1 gp41 Glycoprotein in HIV-1 Mouse Models as a Reagent for HIV Eradication.
by: Ekaterina Dadachova, et al.
Published: (2012-01-01)

Immunoprophylaxis against mother-to-child transmission of HIV-1.
by: Miroslaw K Gorny, et al.
Published: (2006-07-01)

Combination of anti-retroviral drugs and radioimmunotherapy specifically kills infected cells from HIV infected individuals
by: Dina Tsukrov, et al.
Published: (2016-09-01)

Indirect detection of an epitope-specific response to HIV-1 gp120 immunization in human subjects.
by: Evgeny Shmelkov, et al.
Published: (2011-01-01)

Residue 315 regulates V3 exposure and V3 antibody recognition on HIV subtype B and C viruses
by: Manhas S, et al.
Published: (2012-09-01)

Focusing the immune response on the V3 loop of HIV-1 gp120 induces cross-clade neutralizing
by: Wang Shixia, et al.
Published: (2006-12-01)

Attacking latent HIV: towards eradication of HIV infection
by: Margolis DM
Published: (2006-12-01)

The W100 pocket on HIV-1 gp120 penetrated by b12 is not a target for other CD4bs monoclonal antibodies
by: Dueñas-Decamp Maria J, et al.
Published: (2012-01-01)

Different pattern of immunoglobulin gene usage by HIV-1 compared to non-HIV-1 antibodies derived from the same infected subject.
by: Liuzhe Li, et al.
Published: (2012-01-01)

Notes on HIV pathogenesis, therapy and eradication
by: Celia Fernández-Ortega, et al.

CNS reservoirs for HIV: implications for eradication
by: Joanna Hellmuth, et al.
Published: (2015-04-01)

Comparative magnitude of cross-strain conservation of HIV variable loop neutralization epitopes.
by: James Swetnam, et al.
Published: (2010-12-01)

Statistical Data on 2556 Cases of Endocrine Glands Disorders in Iran
by: M. BAHADORI
Published: (1967-01-01)

Statistical Data on 2556 Cases of Endocrine Glands Disorders in Iran
by: M. BAHADORI
Published: (1967-06-01)

Transcriptional profiling of Mycobacterium tuberculosis replicating ex vivo in blood from HIV- and HIV+ subjects.
by: Michelle B Ryndak, et al.
Published: (2014-01-01)

Bispecific Anti-HIV Immunoadhesins That Bind Gp120 and Gp41 Have Broad and Potent HIV-Neutralizing Activity
by: Seth H. Pincus, et al.
Published: (2021-07-01)

HIV-1 gp41 Fusion Intermediate: A Target for HIV Therapeutics
by: Chungen Pan, et al.
Published: (2010-02-01)

Anti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypes.
by: Catarina E Hioe, et al.
Published: (2010-04-01)

HIV-1 gp120 : flexibility and glycosylation
by: Kong, Leopold
Published: (2010)

Eradication of HIV and Cure of AIDS, Now and How?
by: Jie Lin eZhang, et al.
Published: (2013-10-01)

Novel immunological strategies for HIV-1 eradication
by: B. Jülg, et al.
Published: (2015-10-01)

HIV reservoirs in vivo and new strategies for possible eradication of HIV from the reservoir sites
by: Nitin K Saksena, et al.
Published: (2010-06-01)

Targeted killing of virally infected cells by radiolabeled antibodies to viral proteins.
by: Ekaterina Dadachova, et al.
Published: (2006-11-01)

HIV-specific cellular immune responses in HIV-1 and HIV-2 infection
by: Duvall, Melody Gayle
Published: (2006)

Cryptococcus neoformans as a Model for Radioimmunotherapy of Infections
by: Ekaterina Dadachova, et al.
Published: (2011-01-01)

Rational Design of A Novel Small-Molecule HIV-1 Inactivator Targeting Both gp120 and gp41 of HIV-1
by: Jing Pu, et al.
Published: (2021-01-01)

Resistance of Subtype C HIV-1 Strains to Anti-V3 Loop Antibodies
by: David Almond, et al.
Published: (2012-01-01)

Neutralizing Antibodies Targeting HIV-1 gp41
by: Christophe Caillat, et al.
Published: (2020-10-01)

HIV Eradication: Combinatorial Approaches to Activate Latent Viruses
by: Elisa De Crignis, et al.
Published: (2014-11-01)

NOVEL APPROACHES FOR THE ERADICATION OF HIV LATENTLY INFECTED CELLS
by: Al Ali, Sally
Published: (2013)

Antigenicity and immunogenicity of a novel, acute HIV-1 Tanzanian subtype C gp145 envelope protein for clinical development
by: Polonis V, et al.
Published: (2012-09-01)

HIV gp120 induces, NF-kappaB dependent, HIV replication that requires procaspase 8.
by: Gary D Bren, et al.
Published: (2009-01-01)

Striking HIV-1 Entry by Targeting HIV-1 gp41. But, Where Should We Target?
by: Cátia Teixeira, et al.
Published: (2016-01-01)

Development of Protein- and Peptide-Based HIV Entry Inhibitors Targeting gp120 or gp41
by: Jing Pu, et al.
Published: (2019-08-01)

NMR spectroscopy of HIV-1 gp120 outer domain
by: Sastry M, et al.
Published: (2012-09-01)

Characterization of RNA aptamers that bind to HIV-1 gp120
by: Cohen, Carla J.
Published: (2006)

Properties of the C-terminal tail of HIV-1 gp41
by: Hollier, Mark John
Published: (2004)

A clue to unprecedented strategy to HIV eradication: “Lock-in and apoptosis”
by: Hiroshi Tateishi, et al.
Published: (2017-08-01)

Specific eradication of HIV-1 from infected cultured cells
by: Levin Aviad, et al.
Published: (2010-08-01)

Cannot write session to /tmp/vufind_sessions/sess_a0sr5dlsrbabi5duipfkqfh3m9